2-Bromo-4-chloro-1-(trifluoromethoxy)benzene, 97%, 5g

5'-(3-Formyl-4-hydroxyphenyl)-4,4''-dihydroxy-[1,1':3',1''-terphenyl]-3,3''-dicarbaldehyde, 98%, 100mg

N-(3-Bromo-4-methylphenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine, 98%, 25mg

((Oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl) bis(4-methylbenzenesulfonate), 97.0%, 25g

Methyl 2-chloro-4-(methylamino)benzoate hydrochloride, 2.5g

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one, 95.0%, 5g

1,2-Bis(2,4-dimethyl-5-phenyl-3-thienyl)-3,3,4,4,5,5-hexafluoro-1-cyclopentene (purified by sublimation)>99.0%(GC)100mg

4-(BENZYLOXY)-3,3-DIFLUOROPIPERIDINE HCL, 95.0%, 1g

tert-butyl 4-(aminomethyl)piperidine-1-carboxylate;citric acid, 50g

4-(Difluoromethyl)pyrimidine-2-carboxylic acid, 95.0%, 250mg

4-(Aminomethyl)-n-methylbenzene-1-sulfonamide, 95+%, 100mg

Flat flange reaction vial, cylindrical, graduated, with tempering jacket GL connecting piece, DN 150, 3000 ml, 190 mm, 1 Piece

Trimethoxy(methyl)silane>98.0%(GC)500mL